Specifically, treatment of tumor-bearing immune-competent mice with PEG-KYNase elicited statistically significant increases in tumor infiltration and expansion of CD8+ lymphocytes to elicit an anticancer effect (29). The gene discussed is CD8A; the disease is neoplasm.